Drugs / Recombinant Human Bone Morphogenetic Protein-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00384852 | Jan 2007 → Feb 2010 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Bone Morphogenetic Protein-2 | “Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM)” NCT00384852 ↗ |
| Known as | rhBMP-2 | “Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM)” NCT00384852 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Bone Morphogenetic Protein-2” NCT00384852 ↗ |